Evidence map›Paper›PMID 40221882›Full record

ArticleHematological oncology2025

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic Center.

Danai Dima, Utkarsh Goel, Fauzia Ullah, Beth Faiman, Diana Basali, Sandra Mazzoni, Louis S Williams, Christy Samaras, Jason Valent, Faiz Anwer and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Danai DimaCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Utkarsh GoelCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-1663-0325
Fauzia UllahCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Beth FaimanCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Diana BasaliCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Sandra MazzoniCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Louis S WilliamsCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Christy SamarasCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Jason ValentCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Faiz AnwerCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Jack KhouriCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Shahzad RazaCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Localized light chain amyloidosis (loc-AL) is a rare disorder characterized by localized deposition of misfolded AL fibrils. There are limited data on patterns of disease presentation and long-term outcomes. In this study, we retrospectively reviewed 146 patients with loc-AL at our institution between January 1, 2010, and March 1, 2024. We excluded patients with evidence of systemic AL amyloidosis. We calculated local (PFS

Indexed as

Immunoglobulin Light-chain AmyloidosisAcademic Medical CentersAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateTreatment OutcomeAL amyloidosisamyloidosislocalized AL amyloidosislocalized amyloidosisplasma cell disorder

Identifiers

PMID40221882
PMCPMC11993898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.